The study recommends daily methylcobalamin supplementation for metformin-treated type 2 diabetes patients to potentially address neuropathy concerns, supported by increased serum B12 and reduced homocysteine levels

Weekly high-dose cholecalciferol (60,000 IU) with calcium effectively raises vitamin D levels, alleviates myalgia in deficient individuals, outperforming daily low-dose (1000 IU) regimens—a practical and cost-effective solution for addressing vitamin D deficiency.

A combination therapy of Aceclofenac, Paracetamol, Thiocolchicoside, and an H2-receptor antagonist significantly reduces low back pain in 331 patients, surpassing other treatments—a promising strategy for effective management across all age groups.

Ambroxol, a mucokinetic and secretagogue, shows promise in pediatric respiratory care by effectively reducing cough, thoracic symptoms, improving radiological findings, combating antibiotic-resistant infections, and proving well-tolerated—a valuable over-the-counter option for children with respiratory conditions.

A 5-day course of cefuroxime axetil outperforms single-dose fosfomycin trometamol in pregnant women with UTIs, offering quicker recovery and fewer adverse effects.

The PRIDE-2 Study* demonstrated the efficacy of omeprazole-domperidone in relieving APD symptoms in T2DM Indian patients, encompassing GERD, ulcers, and dyspepsia, with good tolerance.

Study suggests alpha-amylase and papain enzyme supplementation for aging Indians can counter deficiencies, enhance digestive function, and improve overall well-being; 83.6% of doctors endorse their combination to address PPI-related issues, promising for elderly individuals' health.

Cefuroxime demonstrates high clinical success in Escherichia coli-induced acute pyelonephritis in women, making it a viable option for initial empirical therapy in community-onset cases, with treatment adjustments based on uropathogen identification and susceptibility results.

A phase II clinical trial in children and adolescents found both PVRV-NG and HDCV rabies vaccines to be highly effective and safe, establishing PVRV-NG as a viable option for rabies prevention in young populations.